talquetamab
janssen
['mmsm', 'multiple myeloma', 'talquetamab']
talquetamab produced responses in more than 70% of patients with relapsed/refractory multiple myeloma who received the recommended phase 2 doses. #ash22 #mmsm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.